Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New scan could spot hidden pancreatic cancer spread

NCT ID NCT07342231

First seen Jan 19, 2026 · Last updated Jun 20, 2026 · Updated 28 times

Summary

This study tests a new type of PET scan that uses a radioactive tracer called FAPi to find pancreatic cancer that standard CT scans might miss. Researchers will scan 60 adults with pancreatic cancer and compare the results to regular CT scans. The goal is to see if this new method can more accurately show how far the cancer has spread, which could help guide treatment decisions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Tata Memorial Hospital, Mumbai, India

    RECRUITING

    Mumbai, Maharashtra, 400012, India

    Contact

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Gallium-68 labeled FAPi (radioactive tracer for PET scan)

What this could lead to

If successful, this could lead to more accurate staging of pancreatic cancer, helping doctors choose better treatments.

What could go wrong

This is a small, early exploratory study with only 60 participants. The new scan may not prove significantly better than current methods, and results may not apply to all patients.

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.